Jefferies Boosts Numbers on Questcor (QCOR) After Including Acthar DM/PM Sales in Model

June 15, 2012 7:27 AM EDT
Get Alerts QCOR Hot Sheet
Price: $93.60 --0%

Rating Summary:
    7 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade QCOR Now!
Join SI Premium – FREE
Jefferies lifted estimates and its price target on Buy-rated Questcor Pharmaceuticals (NASDAQ: QCOR) to $56.00 (from $52.00) after a call from the from the company clarifying its Acthar commercial strategy in rheumatology with initial focus on DM/PM following a peer-review publication of Acthar.

"Given a FDA-approved label, peer-reviewed data and a targeted mktg effort, we now include Acthar DM/PM sales in our valuation," the firm states.

FY12 EPS goes from $2.38 to $2.43 and FY13 EPS goes from $3.05 to $3.13.

For an analyst ratings summary and ratings history on Questcor Pharmaceuticals click here. For more ratings news on Questcor Pharmaceuticals click here.

Shares of Questcor Pharmaceuticals closed at $46.41 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment